Aigyul Izhanova

Prof. Dr. Aigyul Izhanova

internal medicine, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2026 in Diseases
Verified
Journal Article
Open access
PDF file
Sholpan Bolatovna ZhangelovaSholpan Bolatovna Zhangelova
Sholpan Bolatovna Zhangelova
OSOrazbek Sakhov
Orazbek Sakhov
LALyazat Abisheva
Lyazat Abisheva
DPDmitriy Polyakov
Dmitriy Polyakov
FRFarida Rustamova
Farida Rustamova
Nurmukhammad Friba NasrullakyzyNurmukhammad Friba Nasrullakyzy
Nurmukhammad Friba Nasrullakyzy
Background: Optimal platelet inhibition is essential for minimizing both thrombotic and hemorrhagic complications in patients with coronary artery disease (CAD). Although high on-treatment platelet reactivity (HPR) has been consistently associated with adverse clinical outcomes, the relationship between platelet reactivity—measured as P2Y12 reaction units (PRU)—and cardiovascular mortality remains incompletely characterized. In particular, potential non-linear associations have not been adequately explored. Objective: We aimed to investigate the association between PRU and cardiovascular mortality in patients with CAD, with a specific focus on identifying potential non-linear relationships. Methods: We conducted a retrospective observational cohort study including 1000 patients with angiographically confirmed CAD treated at a tertiary cardiology center in Almaty, Kazakhstan, between 2024 and 2025. Platelet reactivity was assessed using the VerifyNow P2Y12 assay. Multivariable logistic regression models were used to identify independent predictors of cardiovascular mortality. To assess potential non-linear associations between PRU and mortality, restricted cubic spline regression was applied with predefined knot placement. Model performance was evaluated in terms of discrimination (C-statistic) and calibration (Hosmer-Lemeshow goodness-of-fit test). Results: In conventional linear regression models, PRU was not independently associated with cardiovascular mortality (odds ratio [OR] ~1.00; p > 0.05). However, spline-based analyses demonstrated a statistically significant non-linear (U-shaped) relationship between PRU and mortality risk (p for non-linearity = X). Both low and high PRU values were associated with increased mortality, whereas intermediate PRU levels corresponded to the lowest observed risk. Additional independent predictors of mortality included advanced age, diabetes mellitus, and elevated inflammatory markers. Conclusions: Our findings reveal a significant non-linear association between platelet reactivity and cardiovascular mortality in patients with CAD. Both insufficient and excessive platelet inhibition appear to confer increased risk, suggesting that optimal PRU targets may lie within an intermediate therapeutic range. These results support a paradigm shift toward more individualized antiplatelet therapy strategies guided by platelet function testing.

29 April 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
GAG Arutyunov
G Arutyunov
ETE Tarlovskaya
E Tarlovskaya
AAAlexander Arutyunov
Alexander Arutyunov
DPDmitry Polyakov
Dmitry Polyakov
YLYu. Lopatin
Yu. Lopatin
MYM Yarigina
M Yarigina
Aim. To assess the effectiveness of vaccination against Omicron and Delta variants according to the international registry "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors" (AKTIV-4).Material and methods. The AKTIV-4 registry included men and women over 18 years of age with a diagnosis of coronavirus disease 2019 (COVID-19) (oropharyngeal and nasopharyngeal swabs, SARS-CoV-2 antibody titers, typical computed tomography performance), undergoing hospital treatment. A total of 3543 patients from 25 medical centers in 7 countries (the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan) were included in the AKTIV-4 registry.Results. The clinical status of patients from the AKTIV-4 registry was more severe than in the AKTIV-1 and AKTIV-2 registries. Patients in the AKTIV-4 registry were older than patients in the AKTIV-1 registry. The inhospital mortality rate in patients in the AKTIV-4 registry was higher (8,41%, p<0,001) than in the population of patients in the AKTIV-1 (7,60%) and AKTIV-2 (4,80%) registries. Of the 3543 patients included in AKTIV-4, 36% were vaccinated. Among the vaccines, Sputnik V (GamCOVID-Vac) was the leader in primary and repeated vaccination, used in 77,8% and 61,0%, respectively. In the population of unvaccinated patients, there were more patients with a high risk of an unfavorable prognosis than in the vaccinated as follows: older age, coronary artery disease, class 3-4 heart failure, atrial fibrillation, chronic kidney disease, and anemia. Unvaccinated patients had a higher volume of lung damage compared to vaccinated patients, and bacterial pneumonia and acute respiratory distress syndrome developed more often. Among those who died in hospital, unvaccinated patients predominated (89,14%). Inhospital mortality for unvaccinated patients was 9,9%, while for vaccinated ones — 3,3% (odds ratio (OR) 0,31 [0,20;0,45], p<0,001). In patients within 3, 4-6, and ≥7 months after vaccination, the mortality rate was 3,12% (OR 0,30 [0,16;0,51], p<0,001), 4,00% (OR 0,39 [0,20;0,67], p<0,001), and 2,96% (OR 0,29 [0,09;0,70], p<0,001). Inhospital mortality of vaccinated patients did not differ significantly depending on the type of vaccine.Conclusion. Vaccination, primarily with Sputnik V, is an independent predictor of survival in hospitalized COVID-19 patients and reduces the risk of death by 62% according to multivariate analysis.

30 June 2026 in Наука и здравоохранение
Verified
Journal Article
Closed access
Nurmukhammad Friba NasrullakyzyNurmukhammad Friba Nasrullakyzy
Nurmukhammad Friba Nasrullakyzy
SZSh.B. Zhangelova
Sh.B. Zhangelova
FRFarida Rustamova
Farida Rustamova
AAAizhan Almukhanova
Aizhan Almukhanova
ASA.B. Sugraliyev
A.B. Sugraliyev
ZSZhanargul Smailova
Zhanargul Smailova
Background:Recurrent ischemic symptoms after coronary artery bypass grafting (CABG) may require repeat percutaneous coronary intervention (PCI). Hypertension is common in coronary artery disease, but its value for predicting repeat revascularization after CABG is uncertain. High residual platelet reactivity (HRPR) may improve risk prediction. Objective: To evaluate the association of arterial hypertension and HRPR with repeat PCI after CABG in patients with recurrent ischemic symptoms. Methods: This retrospective single-center study included 195 patients with prior CABG evaluated for recurrent ischemic symptoms 6-36 months after surgery. Patients were stratified by repeat PCI status. HRPR was assessed using the VerifyNow assay; HRPR was defined as PRU≥208. Clinical and angiographic variables were analyzed using logistic regression. Results:Patients requiring repeat PCI were older and had extensive coronary artery disease and chronic kidney disease. Hypertension prevalence was similar between groups. PRU values were significantly higher in the repeat PCI group (230 vs 145, p<0.001), while HRPR was present in 66.2% of these patients and absent in those without repeat PCI. PRU remained associated with repeat PCI after adjustment. Conclusions: In post-CABG patients with recurrent ischemia, hypertension was not associated with repeat PCI, whereas HRPR showed a strong association with repeat revascularization. Введение:Рецидивирующая ишемия после аортокоронарного шунтирования (АКШ) может потребовать повторного чрескожного коронарного вмешательства (ЧКВ). Роль артериальной гипертензии в прогнозировании повторной реваскуляризации остается неясной, тогда как высокая остаточная реактивность тромбоцитов (ВОРТ) может иметь прогностическое значение. Цель: Оценить ассоциацию артериальной гипертензии и ВОРТ с повторным ЧКВ у пациентов после АКШ с рецидивирующими ишемическими симптомами. Материалы и методы: Ретроспективное одноцентровое исследование включило 195 пациентов после АКШ, обследованных через 6–36 месяцев по поводу рецидивирующей ишемии. Пациенты были разделены по наличию повторного ЧКВ. Реактивность тромбоцитов оценивали методом VerifyNow; HRPRопределяли как PRU ≥208. Данные анализировали с использованием логистической регрессии. Результаты:Пациенты, с повторным ЧКВ, были старше и чаще имели более тяжелое поражение коронарных артерий и хроническую болезнь почек. Частота артериальной гипертензии не различалась между группами. Уровни PRUбыли значительно выше в группе повторного ЧКВ (230 против 145; p<0,001). HRPRвыявлялась у 66,2% пациентов с повторным ЧКВ и отсутствовала в группе без него. PRUсохранял значимую ассоциацию с повторным ЧКВ после корректировки. Выводы: У пациентов после АКШ с рецидивирующей ишемией артериальная гипертензия не связана с повторным ЧКВ, тогда как ВОРТ ассоциируется с повышенным риском повторной реваскуляризации и может иметь прогностическую ценность. Кіріспе: Аортокоронарлық шунттау (АКШ) операциясынан кейін қайталанатын ишемиялық симптомдар қайталама тері арқылы коронарлық араласуды (ТКА) қажет етуі мүмкін. Артериялық гипертензияның қайталама реваскуляризацияны болжаудағы рөлі әлі толық анықталмаған, ал тромбоциттердің жоғары қалдық реактивтілігі (ТЖҚР) болжамдық мәнге ие болуы мүмкін. Мақсаты: АКШ-тан кейін қайталанатын ишемиялық симптомдары бар науқастарда артериялық гипертензия мен ТЖҚР -дың қайталама ТКА-мен байланысын бағалау. Материалдар мен әдістер: Ретроспективті бір орталықты зерттеуге АКШ операциясынан кейін 6–36 ай ішінде қайталанатын ишемияға байланысты тексерілген 195 науқас енгізілді. Науқастар қайталама ТКА-ның болуына қарай топтарға бөлінді. Тромбоциттердің реактивтілігі VerifyNow әдісімен бағаланды; ТЖҚР PRU ≥208 ретінде анықталды. Деректер логистикалық регрессия арқылы талданды. Нәтижелер: Қайталама ЧКВ жасалған науқастар жасы үлкен және коронарлық артериялардың айқын зақымдануы мен созылмалы бүйрек ауруы...

20 November 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Closed access
DADana Akhmentayeva
Dana Akhmentayeva
Zhanar ToktarovaZhanar Toktarova
Zhanar Toktarova
Aigyul IzhanovaAigyul Izhanova
Aigyul Izhanova
Meiramgul TokbulatovaMeiramgul Tokbulatova
Meiramgul Tokbulatova
AIAssel Issabekova
Assel Issabekova
GZG. Kh. Zhansarina
G. Kh. Zhansarina
Introduction . Hyperglycemia is one of the most common pregnancy complications worldwide. The largest proportion of patients are women with gestational diabetes mellitus, followed by pregnant women with previously diagnosed type 1 and type 2 diabetes. Managing such cases is a complex clinical task requiring close cooperation between specialists in various fields. Aim . To analyze the tactics of managing pregnant women with diabetes mellitus to assess predisposing risk factors. Materials and methods. The analysis of modern data was carried out with an emphasis on the role of diabetes mellitus in developing complications during pregnancy. The databases PubMed, Scopus, Web of Science, and eLibrary were used for the analysis. The search was carried out by keywords: gestational diabetes mellitus, pregnancy complications, metabolic disorders, maternal-fetal outcomes, prevention of diabetes in pregnancy. Results . The level of metabolic control at the stage of pregnancy planning has a significant impact on its course and outcome in women with type 1 and type 2 diabetes mellitus. Pre-pregnancy training and professional support of qualified specialists play a key role, often surpassing мнеthe use of modern technologies such as insulin pumps and continuous glucose monitoring systems. Conclusion . Despite the existing methods of prevention and treatment, there remains a need for further study of individualized approaches to the management of pregnant women with metabolic disorders.

4 November 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
YOYelvira Omralina
Yelvira Omralina
Aigyul IzhanovaAigyul Izhanova
Aigyul Izhanova
ABAlina Bulatova
Alina Bulatova
VRVenera Rakhmetova
Venera Rakhmetova
Kassymzhomart ZholamanovKassymzhomart Zholamanov
Kassymzhomart Zholamanov
The issue of early cancer diagnosis today is characterized by late symptom manifestation, difficulties in timely performing diagnostic procedures, and a lack of biomarkers that fully meet the criteria for sensitivity and specificity. An expanded search for novel diagnostic methods currently shows promise regarding the use of altered protein glycosylation patterns. This assumption is grounded in the ability of post-translational modifications, including changes in glycoprotein profiles and glycan structures, to serve as a signal of alterations at the level of synthetic processes. Tumor-associated glycan structures are released into the bloodstream, creating an opportunity for their detection using minimally invasive diagnostic methods. This article summarizes current data on the use of glycan signatures as cancer biomarkers for gastrointestinal and hepatopancreatic systems. The study utilized methodological discoveries in the fields of glycoproteomics and glycomics as informational material, actively integrating modern branches of omics technologies. Mass spectrometry and analytical methods made it possible to identify the most informative glycoproteomic and glycan biomarkers, the diagnostic efficacy of which was evaluated on internal and external validation cohorts. Analysis of the obtained data was performed with consideration of the limitations of the included studies, including small sample sizes, cohort heterogeneity, and potential publication bias. To enhance informativeness by developing new validation panels for early cancer detection, research recommendations for conducting new prospective studies are provided at the end of the review.